Too Old to Operate1h
Nomograms for Predicting Postoperative Outcomes in HCC With CSPH After Resection
The following is a summary of “Development models to predict complication and prognosis following liver resection for ...
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...
Is Your Diet Killing Your DNA? Scientists Uncover Liver Cancer “Ticking Time Bomb”
Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.
Exploring IL-8⁺ neutrophils and their role in severe alcohol-associated hepatitis
Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated ...
Arizona man dies after catching cancer from his organ donor in one-of-a-kind case
In an extremely rare case, an unnamed 69-year-old man who had cirrhosis and liver cancer underwent a liver transplant and ...
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...
Arizona man dies after catching cancer from his organ donor
In an extremely rare case, an unnamed 69-year-old man who had cirrhosis and liver cancer underwent a liver transplant and ...
NAYA Biosciences, Inc.: NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla.
NAYA Biosciences Announces Development Of NY-500, A Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications . NAYA aimi ...
gastroenterologyadvisor23h
Chronic Hepatitis B in the Indeterminate Phase Poses Risks for Adverse Liver Outcomes
Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...